Skip to main content
Top
Published in: Diabetologia 6/2007

01-06-2007 | Article

Variation in the peroxisome proliferator-activated receptor δ gene in relation to common metabolic traits in 7,495 middle-aged white people

Authors: N. Grarup, A. Albrechtsen, J. Ek, K. Borch-Johnsen, T. Jørgensen, O. Schmitz, T. Hansen, O. Pedersen

Published in: Diabetologia | Issue 6/2007

Login to get access

Abstract

Aims/hypothesis

Studies in animals reveal that peroxisome proliferator-activated receptor δ (PPARδ) regulates glucose metabolism and insulin sensitivity in both the liver and skeletal muscles. Moreover, PPARδ augments physical endurance and increases oxidative metabolism, thereby averting obesity. Thus, we hypothesised that common variation in the PPARD gene is associated with insulin resistance and metabolic traits.

Materials and methods

We studied variation in the exonic region of PPARD. Based upon the results of variant detection and information derived from the HapMap data resource, we selected common variants and tag single-nucleotide polymorphisms for genotyping in 7,495 white subjects, including 1,416 patients with type 2 diabetes.

Results

Fourteen nucleotide variants were identified and a total of 12 variants capturing the common variation of PPARD were genotyped. In the population-based Inter99 (ClinicalTrials.gov ID no: NCT00289237) sample we observed no robust association with homeostasis model assessment of insulin resistance (HOMA-IR), adiposity measures or fasting serum lipids. Similarly, no association with type 2 diabetes or the metabolic syndrome was found.

Conclusions/interpretation

Based on thorough investigation, we conclude that common variation in PPARD does not significantly affect the risk of metabolic disease in the population studied. Given the confidence intervals that were found for effect size estimates, we can effectively rule out an increase in HOMA-IR of any tag SNP above 7% per allele, assuming an additive model. Likewise, we can exclude an odds ratio of type 2 diabetes above 1.27 per allele.
Appendix
Available only for authorised users
Literature
1.
go back to reference Andersen G, Hansen T, Pedersen O (2005) Genetics of common forms of glycaemia with pathological impact on vascular biology: are we on the right track? Curr Mol Med 5:261–274PubMedCrossRef Andersen G, Hansen T, Pedersen O (2005) Genetics of common forms of glycaemia with pathological impact on vascular biology: are we on the right track? Curr Mol Med 5:261–274PubMedCrossRef
2.
go back to reference Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 116:571–580PubMedCrossRef Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 116:571–580PubMedCrossRef
3.
go back to reference Semple RK, Chatterjee VK, O’Rahilly S (2006) PPARγ and human metabolic disease. J Clin Invest 116:581–589PubMedCrossRef Semple RK, Chatterjee VK, O’Rahilly S (2006) PPARγ and human metabolic disease. J Clin Invest 116:581–589PubMedCrossRef
4.
go back to reference Chawla A, Lee CH, Barak Y et al (2003) PPARα is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100:1268–1273PubMedCrossRef Chawla A, Lee CH, Barak Y et al (2003) PPARα is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100:1268–1273PubMedCrossRef
5.
go back to reference Lee CH, Kang K, Mehl IR et al (2006) Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc Natl Acad Sci USA 103:2434–2439PubMedCrossRef Lee CH, Kang K, Mehl IR et al (2006) Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc Natl Acad Sci USA 103:2434–2439PubMedCrossRef
6.
go back to reference Wang YX, Zhang CL, Yu RT et al (2004) Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol 2:e294PubMedCrossRef Wang YX, Zhang CL, Yu RT et al (2004) Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol 2:e294PubMedCrossRef
7.
go back to reference Luquet S, Lopez-Soriano J, Holst D et al (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 17:2299–2301PubMed Luquet S, Lopez-Soriano J, Holst D et al (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 17:2299–2301PubMed
8.
go back to reference Lee CH, Olson P, Hevener A et al (2006) PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444–3449PubMedCrossRef Lee CH, Olson P, Hevener A et al (2006) PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444–3449PubMedCrossRef
9.
go back to reference Wang YX, Lee CH, Tiep S et al (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159–170PubMedCrossRef Wang YX, Lee CH, Tiep S et al (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159–170PubMedCrossRef
10.
go back to reference Tanaka T, Yamamoto J, Iwasaki S et al (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924–15929PubMedCrossRef Tanaka T, Yamamoto J, Iwasaki S et al (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924–15929PubMedCrossRef
11.
go back to reference Oliver WR, Shenk JL, Snaith MR et al (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306–5311PubMedCrossRef Oliver WR, Shenk JL, Snaith MR et al (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306–5311PubMedCrossRef
12.
go back to reference Leibowitz MD, Fiévet C, Hennuyer N et al (2000) Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 473:333–336PubMedCrossRef Leibowitz MD, Fiévet C, Hennuyer N et al (2000) Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 473:333–336PubMedCrossRef
13.
go back to reference Watt MJ, Southgate RJ, Holmes AG, Febbraio MA (2004) Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) α and δ and PPAR coactivator 1α in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol 33:533–544PubMedCrossRef Watt MJ, Southgate RJ, Holmes AG, Febbraio MA (2004) Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) α and δ and PPAR coactivator 1α in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol 33:533–544PubMedCrossRef
14.
go back to reference Mahoney DJ, Parise G, Melov S, Safdar A, Tarnopolsky MA (2005) Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise. FASEB J 19:1498–1500PubMed Mahoney DJ, Parise G, Melov S, Safdar A, Tarnopolsky MA (2005) Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise. FASEB J 19:1498–1500PubMed
15.
go back to reference Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E (2003) Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 254:597–604PubMedCrossRef Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E (2003) Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 254:597–604PubMedCrossRef
16.
go back to reference Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E (2003) Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637–643PubMedCrossRef Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E (2003) Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637–643PubMedCrossRef
17.
go back to reference Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of the T+294C polymorphism in PPARδ with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 3:108–111PubMed Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of the T+294C polymorphism in PPARδ with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 3:108–111PubMed
18.
go back to reference Chen S, Tsybouleva N, Ballantyne CM, Gotto AM, Marian AJ (2004) Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14:61–71PubMedCrossRef Chen S, Tsybouleva N, Ballantyne CM, Gotto AM, Marian AJ (2004) Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14:61–71PubMedCrossRef
19.
go back to reference Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W (2005) The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183:336–341PubMedCrossRef Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W (2005) The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183:336–341PubMedCrossRef
20.
go back to reference Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 30:1709–1713CrossRef Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 30:1709–1713CrossRef
21.
go back to reference Robitaille J, Gaudet D, Perusse L, Vohl MC (2007) Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta −87T>C polymorphism and dietary fat in French–Canadians. Int J Obes (Lond) 31:411–417CrossRef Robitaille J, Gaudet D, Perusse L, Vohl MC (2007) Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta −87T>C polymorphism and dietary fat in French–Canadians. Int J Obes (Lond) 31:411–417CrossRef
22.
go back to reference Vänttinen M, Nuutila P, Kuulasmaa T et al (2005) Single nucleotide polymorphisms in the peroxisome proliferator-activated receptorδ gene are associated with skeletal muscle glucose uptake. Diabetes 54:3587–3591PubMedCrossRef Vänttinen M, Nuutila P, Kuulasmaa T et al (2005) Single nucleotide polymorphisms in the peroxisome proliferator-activated receptorδ gene are associated with skeletal muscle glucose uptake. Diabetes 54:3587–3591PubMedCrossRef
23.
go back to reference Andrulionyte L, Peltola P, Chiasson JL, Laakso M (2006) Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 55:2148–2152PubMedCrossRef Andrulionyte L, Peltola P, Chiasson JL, Laakso M (2006) Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 55:2148–2152PubMedCrossRef
24.
go back to reference Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehab 10:377–386CrossRef Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1). Eur J Cardiovasc Prev Rehab 10:377–386CrossRef
25.
go back to reference World Health Organization Study Group (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Tech Rep Ser WHO/NCD/NCS/99, 2nd edn. World Health Organization, Geneva World Health Organization Study Group (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Tech Rep Ser WHO/NCD/NCS/99, 2nd edn. World Health Organization, Geneva
26.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
27.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
28.
go back to reference Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474PubMedCrossRef Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474PubMedCrossRef
29.
go back to reference The International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef The International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef
30.
go back to reference Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120PubMedCrossRef Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120PubMedCrossRef
31.
go back to reference Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434PubMedCrossRef Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434PubMedCrossRef
32.
go back to reference Lake SL, Lyon H, Tantisira K et al (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55:56–65PubMedCrossRef Lake SL, Lyon H, Tantisira K et al (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55:56–65PubMedCrossRef
33.
go back to reference Doerge RW, Churchill GA (1996) Permutation tests for multiple loci affecting a quantitative character. Genetics 142:285–294PubMed Doerge RW, Churchill GA (1996) Permutation tests for multiple loci affecting a quantitative character. Genetics 142:285–294PubMed
34.
go back to reference Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74:765–769PubMedCrossRef Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74:765–769PubMedCrossRef
35.
go back to reference Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef
36.
go back to reference Barish GD, Narkar VA, Evans RM (2006) PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116:590–597PubMedCrossRef Barish GD, Narkar VA, Evans RM (2006) PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116:590–597PubMedCrossRef
37.
go back to reference Shin HD, Park BL, Kim LH et al (2004) Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 53:847–851PubMedCrossRef Shin HD, Park BL, Kim LH et al (2004) Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 53:847–851PubMedCrossRef
38.
go back to reference de Bakker PIW, Burtt NP, Graham RR et al (2006) Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 38:1298–1303PubMedCrossRef de Bakker PIW, Burtt NP, Graham RR et al (2006) Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 38:1298–1303PubMedCrossRef
39.
go back to reference Montpetit A, Nelis M, Laflamme P et al (2006) An evaluation of the performance of tag SNPs derived from HapMap in a Caucasian population. PLoS Genet 2:e27PubMedCrossRef Montpetit A, Nelis M, Laflamme P et al (2006) An evaluation of the performance of tag SNPs derived from HapMap in a Caucasian population. PLoS Genet 2:e27PubMedCrossRef
Metadata
Title
Variation in the peroxisome proliferator-activated receptor δ gene in relation to common metabolic traits in 7,495 middle-aged white people
Authors
N. Grarup
A. Albrechtsen
J. Ek
K. Borch-Johnsen
T. Jørgensen
O. Schmitz
T. Hansen
O. Pedersen
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0668-2

Other articles of this Issue 6/2007

Diabetologia 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.